To support the use of immunotherapy combined with standard chemotherapy treatment, we endeavored in the present study to investigate the activity of bispecific T cell engager, the so-called PD-L1xCD3 BiTE, to overcome incremental PD-L1 expression in CCA after gemcitabine treatment. This evidence concerns the gene CD274 and cholangiocarcinoma.